Tempest Therapeutics Shares Up 19% Premarket. A Press Release Earlier Announced A Presentation On Its Liver Cancer Treatment At ASCO Annual Meeting 2024

-2.13% Pre

Tempest Therapeutics, Inc. - Common Stock

TPST

7.36

-2.13%

0.00% Pre

Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics, today announced its participation in the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. The company presented compelling data highlighting the efficacy and safety of its lead candidate, TPST-1120, a first-in-class PPARα antagonist, in the treatment of liver cancer and other malignancies.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.